Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

Observational studies open to U.S. patients enrolled in Phase 3 VIOLET clinical trials who remain free of disease after 48 weeks

Durham, N.C. – February 11, 2020 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has initiated extension studies as part of its ongoing Phase 3 VIOLET clinical trials for oteseconazole (VT-1161). Mycovia is developing oteseconazole, an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no approved treatment in the U.S.